Cancer Medicine (Aug 2019)
Prognosis and cure of long‐term cancer survivors: A population‐based estimation
- Luigino Dal Maso,
- Chiara Panato,
- Stefano Guzzinati,
- Diego Serraino,
- Silvia Francisci,
- Laura Botta,
- Riccardo Capocaccia,
- Andrea Tavilla,
- Anna Gigli,
- Emanuele Crocetti,
- Massimo Rugge,
- Giovanna Tagliabue,
- Rosa Angela Filiberti,
- Giuliano Carrozzi,
- Maria Michiara,
- Stefano Ferretti,
- Rosaria Cesaraccio,
- Rosario Tumino,
- Fabio Falcini,
- Fabrizio Stracci,
- Antonietta Torrisi,
- Guido Mazzoleni,
- Mario Fusco,
- Stefano Rosso,
- Francesco Tisano,
- Anna Clara Fanetti,
- Giovanna Maria Sini,
- Carlotta Buzzoni,
- Roberta De Angelis,
- AIRTUM Working group
Affiliations
- Luigino Dal Maso
- Cancer Epidemiology Unit Centro di Riferimento Oncologico di Aviano (CRO) IRCCS Aviano Italy
- Chiara Panato
- Cancer Epidemiology Unit Centro di Riferimento Oncologico di Aviano (CRO) IRCCS Aviano Italy
- Stefano Guzzinati
- Veneto Tumour Registry Azienda Zero Padua Italy
- Diego Serraino
- Cancer Epidemiology Unit Centro di Riferimento Oncologico di Aviano (CRO) IRCCS Aviano Italy
- Silvia Francisci
- National Center for Prevention and Health Promotion Italian National Institute of Health (ISS) Rome Italy
- Laura Botta
- Evaluative Epidemiology Unit, Department of Preventive and Predictive Medicine Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy
- Riccardo Capocaccia
- Cancer Epidemiology Unit Centro di Riferimento Oncologico di Aviano (CRO) IRCCS Aviano Italy
- Andrea Tavilla
- National Center for Prevention and Health Promotion Italian National Institute of Health (ISS) Rome Italy
- Anna Gigli
- Institute for Research on Population and Social Policies National Research Council Rome Italy
- Emanuele Crocetti
- Romagna Cancer Registry Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS and Azienda Usl della Romagna Meldola (Forlì) Italy
- Massimo Rugge
- Veneto Tumour Registry Azienda Zero Padua Italy
- Giovanna Tagliabue
- Lombardy Cancer Registry-Varese Province, Cancer Registry Unit, Department of Research Fondazione IRCCS Istituto Nazionale Tumori Milan Italy
- Rosa Angela Filiberti
- Liguria Cancer Registry, Clinical Epidemiology IRCCS Policlinico San Martino Genova Italy
- Giuliano Carrozzi
- Modena Cancer Registry, Public Health Department AUSL Modena Modena Italy
- Maria Michiara
- Parma Cancer Registry, Oncology Unit Azienda Ospedaliera Universitaria di Parma Parma Italy
- Stefano Ferretti
- Romagna Cancer Registry ‐ Section of Ferrara. Local Health Unit University of Ferrara Ferrara Italy
- Rosaria Cesaraccio
- North Sardinia Cancer Registry Azienda Regionale per la Tutela della Salute Sassari Italy
- Rosario Tumino
- Cancer Registry ASP Ragusa Victoria Italy
- Fabio Falcini
- Romagna Cancer Registry Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS and Azienda Usl della Romagna Meldola (Forlì) Italy
- Fabrizio Stracci
- Public Health Section, Department of Experimental Medicine University of Perugia Perugia Italy
- Antonietta Torrisi
- Registro Tumori Integrato Catania‐Messina‐Siracusa‐Enna Catania Italy
- Guido Mazzoleni
- South‐Tyrol Tumor Registry Bolzano Italy
- Mario Fusco
- Cancer Registry of ASL Napoli 3 Sud Napoli Italy
- Stefano Rosso
- Registro Tumori Piemonte Provincia di Biella CPO Biella Italy
- Francesco Tisano
- Cancer Registry of the Province of Siracusa Local Health Unit of Siracusa Siracusa Italy
- Anna Clara Fanetti
- Sondrio Cancer Registry, Epidemiology unit ATS della Montagna Sondrio Italy
- Giovanna Maria Sini
- Nuoro Cancer Registry ASSL Nuoro/ATS Sardegna Nuoro Italy
- Carlotta Buzzoni
- Tuscany Cancer Registry Clinical and Descriptive Epidemiology Unit, Cancer Prevention and Research Institute (ISPO) Florence Italy
- Roberta De Angelis
- Department of Oncology and Molecular Medicine Italian National Institute of Health (ISS) Rome Italy
- AIRTUM Working group
- DOI
- https://doi.org/10.1002/cam4.2276
- Journal volume & issue
-
Vol. 8,
no. 9
pp. 4497 – 4507
Abstract
Abstract Background Increasing evidence of cure for some neoplasms has emerged in recent years. The study aimed to estimate population‐based indicators of cancer cure. Methods Information on more than half a million cancer patients aged 15‐74 years collected by population‐based Italian cancer registries and mixture cure models were used to estimate the life expectancy of fatal tumors (LEFT), proportions of patients with similar death rates of the general population (cure fraction), and time to reach 5‐year conditional relative survival (CRS) >90% or 95% (time to cure). Results Between 1990 and 2000, the median LEFT increased >1 year for breast (from 8.1 to 9.4 years) and prostate cancers (from 5.2 to 7.4 years). Median LEFT in 1990 was >5 years for testicular cancers (5.8) and Hodgkin lymphoma (6.3) below 45 years of age. In both sexes, it was ≤0.5 years for pancreatic cancers and NHL in 1990 and in 2000. The cure fraction showed a 10% increase between 1990 and 2000. It was 95% for thyroid cancer in women, 94% for testis, 75% for prostate, 67% for breast cancers, and 95% was 90% was reached in 15 years. Conclusions The study findings confirmed that several cancer types are curable. Became aware of the possibility of cancer cure has relevant clinical and social impacts.
Keywords
